Neutropine is primarily used to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving cytotoxic chemotherapy, excluding chronic myeloid leukemia and myelodysplastic syndromes.

Yes, it is indicated for the autologous mobilization of progenitor cells into peripheral blood or following myelosuppressive chemotherapy, as well as for allogeneic mobilization in healthy donors.

Yes, the administration of Neutropine is indicated for both children and adults with severe chronic neutropenia.